Evidence map›Paper›PMID 42313302›Full record

ArticleEJNMMI research2026

Impact of different PSMA PET-based eligibility criteria on outcome of [

Sonia Grigorascu, Thomas Langbein, Isabel Rauscher, Kimberley Hansen, Theo Lorenzini, Wolfgang A Weber, Türkay Hekimsoy, Lena Unterrainer, Matthias Eiber

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. FDG/PSMA discordance in [Frontiers in oncology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sonia GrigorascuDepartment of Nuclear Medicine, School of Medicine and Health, TUM University Clinic, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany. sonia.grigorascu@mri.tum.de.ORCID http://orcid.org/0009-0007-1861-3955
Thomas LangbeinDepartment of Nuclear Medicine, School of Medicine and Health, TUM University Clinic, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Isabel RauscherDepartment of Nuclear Medicine, School of Medicine and Health, TUM University Clinic, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Kimberley HansenDepartment of Nuclear Medicine, School of Medicine and Health, TUM University Clinic, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Theo LorenziniDepartment of Nuclear Medicine, School of Medicine and Health, TUM University Clinic, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Wolfgang A WeberDepartment of Nuclear Medicine, School of Medicine and Health, TUM University Clinic, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Türkay HekimsoyDepartment of Nuclear Medicine, School of Medicine and Health, TUM University Clinic, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Lena Unterrainer *Department of Nuclear Medicine, School of Medicine and Health, TUM University Clinic, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Matthias Eiber *Department of Nuclear Medicine, School of Medicine and Health, TUM University Clinic, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background[

resultsIn total, 191 mCRPC patients from our institutional database were included, of which 138 underwent [

conclusionMultiple similarities between BET and VISION eligibility criteria (V + /B +) prior to [

Indexed as

[177Lu]Lu-rhPSMA-10.1[18F]rhPSMA-7.3EligibilityProstate cancerPSMA therapyVISION

Identifiers

PMID42313302
PMCPMC13280062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.